Allspring Global Investments Holdings LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 20.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 544,291 shares of the company's stock after buying an additional 92,693 shares during the period. Allspring Global Investments Holdings LLC's holdings in Johnson & Johnson were worth $78,389,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in JNJ. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the third quarter worth about $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the third quarter worth about $35,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the period. Institutional investors own 69.55% of the company's stock.
In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by company insiders.
JNJ traded down $1.05 during mid-day trading on Friday, reaching $156.20. 6,402,249 shares of the company traded hands, compared to its average volume of 9,304,454. The stock has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company's fifty day moving average price is $147.87 and its 200-day moving average price is $155.96. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.
JNJ has been the topic of several analyst reports. Barclays lifted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price target on the stock. Morgan Stanley reduced their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Finally, Argus upgraded Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.67.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.